Calibrant Announces Brain Cancer Drug Discovery Program With Cleveland Clinic

Main Category: Cancer / Oncology
Also Included In: Neurology / Neuroscience
Article Date: 28 Jan 2008 - 3:00 PDT

email to a friend   printer friendly   opinions  

Calibrant Biosystems announced a research collaboration with the Cleveland Clinic to identify novel drug targets for primary brain cancer using Calibrant's Gemini proteomics platform. As part of the partnership, Calibrant will identify protein networks and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma multiforme (GBM).

"Our collaboration represents another important cancer drug program for Calibrant," stated Dr. Brian Balgley, Chief Technology Officer of Calibrant Biosystems. "The study reflects Calibrant's ability to apply the Gemini platform to targeted discovery from microdissected cell populations for the effective identification of disease-relevant pathways and drug targets." Calibrant's collaborator, Robert J. Weil, M.D., is the Melvin Burkhardt Chair of Brain Tumor Research and Director of Laboratory Research in the Brain Tumor & Neuro-Oncology Center at Cleveland Clinic.

This latest partnership with the Cleveland Clinic adds tremendous value to Calibrant's existing drug discovery collaborations. Calibrant has recently established several drug discovery collaborations with world-renowned medical research centers this year, leading to active therapeutic programs for cancer indications including breast and ovarian cancer.

About Calibrant Biosystems

Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrant's advanced Gemini discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the unique ability to comparatively map protein networks between different cell types within a single tissue section. With an initial focus on monoclonal antibody drug development in oncology, Calibrant is leveraging the Gemini platform for the development of first-in-class therapeutics across a range of cancer indications.

Calibrant Biosystems

• Additional
• References
• Citations